MA40030A - Conjugués peptide-médicament - Google Patents

Conjugués peptide-médicament

Info

Publication number
MA40030A
MA40030A MA040030A MA40030A MA40030A MA 40030 A MA40030 A MA 40030A MA 040030 A MA040030 A MA 040030A MA 40030 A MA40030 A MA 40030A MA 40030 A MA40030 A MA 40030A
Authority
MA
Morocco
Prior art keywords
peptide
drug conjugates
linker
self
drug
Prior art date
Application number
MA040030A
Other languages
English (en)
Inventor
Shaosong Chu
Original Assignee
Jiarui Biopharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiarui Biopharmaceuticals Ltd filed Critical Jiarui Biopharmaceuticals Ltd
Publication of MA40030A publication Critical patent/MA40030A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur des conjugués peptide-médicament comprenant des lieurs à auto-immolation de carbonate de p-aminobenzylcarbamoyle ou de p-aminobenzolyle. Les conjugués peptide-médicament comprennent une fraction peptidique qui peut être clivée par des protéases cellulaires, liées au lieur à auto-immolation, lequel lieur est lié à une fraction de médicament cytotoxique. Lors du clivage de la fraction peptidique, le lieur s'auto-immole, libérant le médicament cytotoxique sous une forme active. L'invention porte également sur des structures dimères des conjugués peptide-médicament comprenant deux molécules de médicament cytotoxique par conjugué.
MA040030A 2014-06-03 2015-06-01 Conjugués peptide-médicament MA40030A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462007159P 2014-06-03 2014-06-03

Publications (1)

Publication Number Publication Date
MA40030A true MA40030A (fr) 2015-12-10

Family

ID=54700553

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040030A MA40030A (fr) 2014-06-03 2015-06-01 Conjugués peptide-médicament

Country Status (9)

Country Link
US (2) US9579317B2 (fr)
EP (1) EP3152223B1 (fr)
JP (2) JP6539729B2 (fr)
CN (1) CN106456799B (fr)
AU (1) AU2015270924B2 (fr)
CA (1) CA2951049C (fr)
ES (1) ES2857192T3 (fr)
MA (1) MA40030A (fr)
WO (1) WO2015187540A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016026458A1 (fr) * 2014-08-22 2016-02-25 亚飞（上海）生物医药科技有限公司 Corps de couplage à cible micromoléculaire activée de manière spécifique dans un micro-environnement tumoral et son utilisation
MX2018011627A (es) 2016-03-24 2019-01-10 Bayer Pharma AG Profarmacos de farmacos citotoxicos que tienen grupos enzimaticamente escindibles.
CN107375288B (zh) * 2016-05-16 2019-08-23 博瑞生物医药（苏州）股份有限公司 多臂的聚合靶向抗癌偶联物
CA3047491A1 (fr) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Promedicaments de principes actifs cytotoxiques contenant des groupes divisibles par voie enzymatique
CN108314703B (zh) * 2017-01-17 2022-02-01 亚飞（上海）生物医药科技有限公司 分子定点靶向和激活的激酶抑制剂的制备和用途
CA3058029A1 (fr) * 2017-04-21 2018-10-25 Brightgene Bio-Medical Technology Co., Ltd. Conjugue anticancereux cible a bras multiples
CN107670048B (zh) 2017-08-30 2019-04-26 南京明臻医药科技有限公司 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用
US20220064214A1 (en) * 2019-01-07 2022-03-03 Cenna Biosciences Inc. Novel peptides and uses thereof
KR20210150496A (ko) * 2019-04-05 2021-12-10 프로린크스 엘엘시 개선된 컨쥬게이션 링커
US20220313625A1 (en) * 2019-05-24 2022-10-06 The Jikei University Pharmaceutical agent, medicinal solution for cleaning pulmonary alveoli, and nebulizer
CN115850288A (zh) * 2022-11-25 2023-03-28 深圳先进技术研究院 一种丝裂霉素c前体药物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3803223A (en) * 1970-07-20 1974-04-09 Searle & Co 3-amino-n-substituted succinamic acids and intermediates thereto
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
CA2399255A1 (fr) * 2000-02-24 2001-08-30 Genentech, Inc. Therapie par promedicaments actives par une caspase
US8314060B2 (en) 2000-09-05 2012-11-20 Biosight Ltd. Peptide conjugated anti-cancer prodrugs
EP1635858A4 (fr) * 2003-05-29 2009-08-26 Scripps Research Inst Liberation ciblee sur des cellules exprimant la legumaine
EP1976861A2 (fr) * 2005-11-29 2008-10-08 The Scripps Research Institute Inhibition de l'invasion des cellules tumorales, de la metastase et de l'angiogenese
EP2266964B1 (fr) * 2009-06-22 2013-01-09 KTB Tumorforschungsgesellschaft mbH Unités de déclencheur d'acide labile
US8394922B2 (en) * 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
US20140057844A1 (en) 2010-12-03 2014-02-27 Tin Tin Su Chemical entities and therapeutic uses thereof

Also Published As

Publication number Publication date
EP3152223A1 (fr) 2017-04-12
US20150343083A1 (en) 2015-12-03
EP3152223A4 (fr) 2017-12-20
CA2951049A1 (fr) 2015-12-10
AU2015270924A1 (en) 2016-12-15
ES2857192T3 (es) 2021-09-28
AU2015270924B2 (en) 2019-09-12
WO2015187540A1 (fr) 2015-12-10
JP6539729B2 (ja) 2019-07-03
CN106456799B (zh) 2020-05-22
CA2951049C (fr) 2023-01-03
JP2019189623A (ja) 2019-10-31
US9579317B2 (en) 2017-02-28
JP2017521486A (ja) 2017-08-03
CN106456799A (zh) 2017-02-22
EP3152223B1 (fr) 2020-11-25
US20170232023A1 (en) 2017-08-17

Similar Documents

Publication Publication Date Title
MA40030A (fr) Conjugués peptide-médicament
PH12018500693A1 (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
PH12019501056A1 (en) Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
NZ720743A (en) Peptidomimetic compounds and antibody-drug conjugates thereof
CY1123675T1 (el) Πολυαιθυλενογλυκολιωμενου φαρμακου-συνδετες για βελτιωμενες φαρμακοκινητικες προϊοντος συζευξης προσδετη-φαρμακου
PH12016501995A1 (en) Tubulysin derivatives
ZA201805336B (en) Amanitin conjugates
PH12016500246A1 (en) 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
MX2021008334A (es) Ligadores que modulan la estabilidad para usar con conjugados anticuerpo-farmaco.
NZ754810A (en) Pyrrolobenzodiazepine-antibody conjugates
MX2021010550A (es) Conjugados de anticuerpo-farmaco hidrofilicos.
PH12016501171A1 (en) Peptidomimetic compounds and antibody-drug conjugates thereof
AR088694A1 (es) Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos
WO2014062697A3 (fr) Conjugués d'administration de médicament contenant des acides aminés artificiels et procédés d'utilisation
PH12015501422B1 (en) Hydrophilic self-immolative linkers and conjugates thereof
MX2013003452A (es) Conjugados de amatoxina con enlazantes mejorados.
NZ703581A (en) Anti-cd70 antibody drug conjugates
NZ710729A (en) Amatoxin derivatives
IN2015DN02577A (fr)
MY169147A (en) Drug-protein conjugates
MX2016007578A (es) Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento.
MX2013010286A (es) Conjugados de amatoxinas con enlaces mejorados.
MX2018001723A (es) Conjugados farmaco-multiligando y usos de los mismos.
AR095072A1 (es) Conjugados antibióticos
GB2538023A (en) Targeted drug conjugates